Skip to main navigation
Skip to main content
Skip to Footer
Google Tag Manager
US
Novartis site directory
Our Products
US Products By Brand
Product Portfolio
Our Process
Therapeutic Areas
Patient Assistance
Product Related Issues
About Us
Who We Are
Our Business
Diversity and Inclusion
Supplier Diversity
Research
Contact Us
Corporate Responsibility
Novartis in Society US Reports
Corporate Citizenship
Business Conduct
Corporate Integrity Agreement
Payments to Healthcare Professionals
Payments to Healthcare Organizations
Physician Payments - Sunshine Act
Post-Marketing Commitments
Enhanced Verification Request
News
News Archive
Statements
Stories
US Media Contacts
Novartis US COVID-19 Initiatives
Careers
Careers Search
Working at Novartis
Employee Benefits
Awards & Recognition
NIBR Careers Frequently Asked Questions
Search
News Archive
Advanced Search
Basic Search
From Date:
To Date:
Show:
All
Media Releases
Stories
Filter By
2020
May
Media Release
/
May 06, 2020
Novartis announces FDA approval of MET inhibitor Tabrecta™ for metastatic non-small cell lung cancer with METex14
Read More
April
Media Release
/
Apr 30, 2020
Novartis US Foundation supports telehealth programs to provide access to care for New Jersey's most vulnerable communities
Read More
Story
/
Apr 23, 2020
The STEP Program™: Supporting Solutions from Patient Advocacy Organizations
Read More
Media Release
/
Apr 03, 2020
Novartis and the Novartis US Foundation establish USD 5 million US COVID-19 Community Response Fund
Read More
March
Media Release
/
Mar 28, 2020
Novartis new analysis further shows durable and potent LDL-C reduction with inclisiran, an investigational first-in-class siRNA cholesterol-lowering treatment
Read More
Media Release
/
Mar 18, 2020
Novartis announces NEJM publication of three pivotal trials showing durable and potent efficacy of inclisiran, an investigational first-in-class siRNA cholesterol-lowering therapy
Read More
Media Release
/
Mar 18, 2020
Novartis Pharmaceuticals Corporation corrective action for certain blister packages of SANDIMMUNE® and NEORAL® 100-mg soft gelatin capsules in the US due to failure to meet child-resistant packaging requirements
Read More
Search Results Navigation
Current page
1
of 5
Page
2
of 5
Page
3
of 5
Page
4
of 5
Page
5
of 5
…
Next page
next ›
Last page
last »
Share
Email
Jump to Comments
Print
Save
Related Links
Novartis joins the Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) initiative
You are here
Home
›
News
